Hypercube Platform from Mendel Now Available in the Microsoft Azure Marketplace

Microsoft Azure customers worldwide now gain access to Mendel’s Hypercube Platform to leverage advanced AI-driven clinical data analytics, enhancing healthcare decision-making with the scalability, reliability, and agility of Azure to drive application development and shape business strategies.

San Jose, California — September 3, 2024 — Mendel, a leader in clinical artificial intelligence, today announced the availability of the Hypercube Platform in the Microsoft Azure Marketplace, an online store providing applications and services for use on Azure. Mendel customers can now take advantage of the productive and trusted Azure cloud platform, with streamlined deployment and management.

Mendel’s Hypercube Platform is a comprehensive clinical data analytics solution that enables healthcare organizations to unlock insights from vast amounts of structured and unstructured data. Leveraging Mendel’s proprietary AI that couples large language models with a clinical hypergraph, Hypercube transforms fragmented data into meaningful clinical insights, accelerating research and improving patient care. Leading life science companies use Hypercube for patient recruitment, patient cohort identification, chart review, and analytical queries.

“Our collaboration with Microsoft Azure marks a significant milestone for Mendel as we expand the accessibility of our Hypercube Platform,” said Dr. Karim Galil, CEO of Mendel. “By offering our platform on Azure, we empower healthcare organizations with the tools needed to unlock the full potential of their data, ensuring better care delivery through precise and data-driven decisions.”

Jake Zborowski, General Manager, Microsoft Azure Platform at Microsoft Corp., said, “We welcome Hypercube Platform to Azure Marketplace, where global customers can find, try, and buy from among thousands of partner solutions. Thanks to trusted collaborators like Mendel, Azure Marketplace is part of a cloud marketplace landscape predicted to grow revenue 500% from 2022 to 2025.”

The Azure Marketplace is an online market for buying and selling cloud solutions certified to run on Azure. The Azure Marketplace helps connect companies seeking innovative, cloud-based solutions with partners who have developed solutions that are ready to use.

Learn more about Hypercube Platform at its page in the Azure Marketplace.

About Mendel: Mendel AI supercharges clinical data workflows by coupling large language models with a proprietary clinical hypergraph, delivering scalable clinical reasoning without hallucinations and ensuring 100% explainability. Headquartered in San Jose, California, Mendel is backed by blue-chip investors, including Oak HC/FT and DCM.

For more information, visit Mendel or contact marketing@mendel.ai.

Mendel joins Google Cloud Partner Advantage and delivers Hypercube through Google Cloud Marketplace

Empowering life science organizations to unlock the power of generative AI with 100% explainability and limited hallucinations

San Jose, Calif., Aug. 20, 2024 — Mendel announced today that it has joined Google Cloud Partner Advantage as a Partner level partner for the Build Engagement Model, giving customers the ability to access Hypercube on Google Cloud Marketplace.

As a Google Cloud partner, Mendel offers healthcare and life science customers a suite of AI-powered tools designed to transform clinical data analytics workflows. Mendel's Hypercube leverages an AI platform that couples large language models with a clinical hypergraph to unlock the vast potential of clinical data warehouses, enabling life science organizations to make more informed, data-driven decisions and improve patient outcomes.

Key features of Mendel's Hypercube platform include:

• Hypercube Cohort: Rapidly create and refine patient cohorts with 5x increase in accuracy and scale.
• Hypercube Charts: Chat with medical records through a user-friendly interface, completing chart reviews with 30%+ more efficiency.
• Hypercube Analyst: Query clinical data with a low-code interface, enabling 10x faster querying.
• Hypercube Redact: De-identify and tokenize patient records with >99% accuracy.
• Hypercube Build-Your-Own (BYO): Customize AI co-pilots for specific data needs and challenges.

"Our partnership with Google Cloud marks a significant milestone in our mission to accelerate the adoption of AI in healthcare," said Dr. Karim Galil, co-founder and CEO of Mendel. "By combining our innovative clinical AI technology with Google Cloud's extensive computational resources and global reach, we're empowering healthcare professionals to provide the best possible care for their patients through data-driven insights."

“Bringing Hypercube to Google Cloud Marketplace will help customers quickly deploy, manage, and grow the Hypercube on Google Cloud's trusted, global infrastructure," said Dai Vu, managing director, Marketplace & ISV GTM Programs at Google Cloud. “Mendel can securely scale and support customers on their digital transformation journeys.”

Life science organizations interested in leveraging Mendel's Hypercube platform can now easily access and deploy it through Google Cloud Marketplace. To learn more about how Mendel is revolutionizing clinical data analytics, visit our marketplace listing here.

About Mendel: 

Mendel AI supercharges clinical data workflows by coupling large language models with a proprietary clinical hypergraph, delivering scalable clinical reasoning without hallucinations and ensuring 100% explainability. Headquartered in San Jose, California, Mendel is backed by blue-chip investors, including Oak HC/FT and DCM.

For more information, visit www.mendel.ai or contact marketing@mendel.ai

‍Media Contact: Jessica McNellis (jessica@galestrategies.com)

‍

Mendel and UMass Amherst Unveil Groundbreaking Research on AI-driven Hallucination Detection in Healthcare

Innovative framework developed to ensure the accuracy and reliability of AI-generated medical summaries.

San Jose, CA, and Amherst, MA - August 6, 2024 – Mendel, a leader in Clinical AI, and the University of Massachusetts Amherst (UMass Amherst) have jointly published pioneering research addressing the critical issue of faithfulness hallucinations in AI-generated medical summaries. This collaborative effort marks a significant advancement in ensuring the safety and reliability of AI applications in healthcare settings.

Research Overview

In recent years, large language models (LLMs) such as GPT-4o and Llama-3 have shown remarkable capabilities in generating medical summaries. However, the risk of hallucinations—where AI outputs include false or misleading information—remains a significant concern. This study aimed to systematically detect and categorize these hallucinations to improve the trustworthiness of AI in clinical contexts.

The research team developed a robust hallucination detection framework, categorizing hallucinations into five subtypes of medical event inconsistency, incorrect reasoning, and chronological inconsistency. A pilot study of 100 summaries from GPT-4o and Llama-3 models revealed that GPT-4o produced longer summaries (>500 words) and often made bold, two-step reasoning statements, leading to hallucinations. Llama-3 hallucinated less by avoiding extensive inferences, but its summaries were of lower quality.  The table below reports the number of model summaries, out of 50 summaries per model, that contains incorrect information according the source medical records:

“Our findings highlight the critical risks posed by hallucinations in AI-generated medical summaries,” said Andrew McCallum, Distinguished Professor of Computer Science, University of Massachusetts Amherst.  “Ensuring the accuracy of these models is paramount to preventing potential misdiagnoses and inappropriate treatments in healthcare.”

The study also explored automated detection methods to mitigate the high costs and time associated with human annotations. The Hypercube system, leveraging medical knowledge bases, symbolic reasoning and NLP, played a crucial role in detecting hallucinations. It provided a comprehensive representation of patient documents, aiding in the initial detection step before human expert review.

“We are committed to continually enhancing Hypercube’s capabilities. The future of healthcare AI depends on reliable, accurate tools, and Hypercube’s evolving features, including real-time data processing and adaptive learning algorithms, will keep it at the forefront of clinical innovation,” said Dr. Wael Salloum, Chief Scientific Officer of Mendel AI.

Future Prospects

As AI continues to integrate into healthcare, addressing hallucinations in LLM outputs will be vital. Future research will focus on refining detection frameworks and exploring more advanced automated systems like Hypercube to ensure the highest levels of accuracy and reliability in AI-generated medical content. Hypercube's real-time data processing and adaptive learning algorithms will be essential in maintaining its position at the forefront of clinical innovation.

Accepted Paper

Mendel's work on Hypercube in detecting hallucinations is recognized by the academic community. The research paper is accepted for oral presentation at the KDD AI conference, August 2024: “Faithfulness Hallucination Detection in Healthcare AI. Prathiksha Rumale V*, Simran Tiwari*, Tejas G Naik*, Sahil Gupta*, Dung N Thai*, Wenlong Zhao*, Sunjae Kwon, Victor Ardulov, Karim Tarabishy, Andrew McCallum, Wael Salloum”. It details the methodologies and technologies underpinning Hypercube’s success.

For more information about the Hypercube platform try the Hypercube demo.

About Mendel

Mendel AI supercharges clinical data workflows by coupling large language models with a proprietary clinical hypergraph, delivering scalable clinical reasoning without hallucinations and ensuring 100% explainability. Headquartered in San Jose, California, Mendel is backed by blue-chip investors, including Oak HC/FT and DCM. For more information, visit Mendel or contact marketing@mendel.ai.

About UMass Amherst

UMass Amherst, the flagship campus of the University of Massachusetts system, is a nationally ranked public research university known for its excellence in teaching, research, and community engagement. The university fosters innovation and collaboration across a wide range of disciplines. For more information, visit UMass Amherst.

Press Contact:

Jessica McNellis

Gale Strategies

Jessica@GaleStrategies.com

‍

Mendel AI Joins NVIDIA Inception Program to Accelerate AI Innovations in Life Sciences

SAN JOSE, Calif. - July 15, 2024 /PRNewswire/

Mendel AI, a leader in clinical AI for the life sciences industry, today announced it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

By joining NVIDIA Inception, Mendel will receive access to NVIDIA’s industry-leading technology, including the latest NVIDIA NIM inference microservices to accelerate Mendel's Hypercube AI solution, and technical expertise in artificial intelligence, deep learning and data science. The resources from the program will help Mendel bring sophisticated, reliable and explainable AI solutions to the healthcare sector that are not only powerful but also responsible and tailored to meet the high stakes of medical decision-making.

"We are incredibly excited to share that Mendel AI has joined NVIDIA Inception, marking a significant milestone in our ongoing efforts to redefine the possibilities of AI in healthcare," said Karim Galil, CEO of Mendel AI. "By integrating NVIDIA's cutting-edge AI tools, we aim to enhance our platform's capabilities, specifically in processing and understanding complex, unstructured medical data at an unprecedented scale. With the program’s resources and together with other forward-thinking companies, we are committed to pushing the boundaries of what AI can achieve in medical research and patient care, aiming to ensure that our technology continues to lead the way in efficiency and effectiveness."

Mendel’s innovative approach to creating clinician-like AI was included in a recent NVIDIA blog post, highlighting Mendel’s applications across clinical research, real-world evidence generation and cohort selection.

NVIDIA Inception helps startups during critical stages of product development, prototyping and deployment. Every Inception member gets a custom set of ongoing benefits, such as NVIDIA Training credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.

About Mendel AI:

Mendel AI supercharges clinical data workflows by coupling large language models with a proprietary clinical hypergraph, delivering scalable clinical reasoning without hallucinations and ensuring 100% explainability. Headquartered in San Jose, California, Mendel is backed by blue-chip investors, including Oak HC/FT and DCM.

For more information, visit www.mendel.ai or contact marketing@mendel.ai

‍

Media Contact

Sylvia Aranda (on behalf of Mendel)

saranda@realchemistry.com

‍